Abstract: Med. Forum, Vol. 36, No. 4
31
April, 2025
Original Article
Assessment of the Anticoagulant
Effect of Curcumin as Adjuvant Therapy to
Enoxaparinin Covid-19 Iraqi Patients
Anticoagulant
Effect of
Curcumin in
Covid-19
Maiss S. Baqer1, Saifan A Dushan1, Rafif Raad1, Rabab Mohammed Noori Hameed1,
Ayaashraf Ahmed1 and Basim Dhawi Dakhil2
ABSTRACT
Objective: To assess the anticoagulant effect of curcumin as adjuvant treatment to enoxaparin in COVID-19
patients.
Study Design: Randomized open-labelled controlled trial study.
Place and Duration of Study: This study was conducted at the College of Pharmacy, Al-Esraa University,
Baghdad, Iraq from 1st February 2020 to 31st July 2020.
Methods: Fifty-eight patients with confirmed Covid19 were enrolled into 2 groups: Group A; 29 patients were
given Enoxaparin prophylactic dose 4000 IU twice daily every 12 hrs. Group B; 29 patients were given Enoxaparin
prophylactic dose 4000 IU twice daily every 12 hrs + Curcumin 500 mg 3 times daily.
Results: A significantly higher level of improvement in the outcomes of D-dimer serum level in the group treated
with enoxaparin and curcumin in comparison with group A which was treated with enoxaparin alone (P<0.05).
Conclusion: The overall results of this clinical study showed a significant D-dimer reduction by curcumin
supplementation as well as reducing mortality and enhancing the overall clinical outcome of the treatment when
used as an adjunct to enoxaparin.
Key Words: Curcumin, D-dimer, Enoxaparin, COVID-19, Anticoagulant effect
Citation of article: Baqer MS, Dushan SA, Raad R, Hameed RMN, Ahmed A, Dakhil BD. Assessment of the
Anticoagulant Effect of Curcumin as Adjuvant Therapy to Enoxaparinin Covid-19 Iraqi Patients. Med
Forum 2025;36(4):31-34. doi:10.60110/medforum.360407.
DOI record:
{
"DOI": "10.60110/medforum.360407",
"ISSN": [
"2519-7134",
"1029-385X"
],
"URL": "http://dx.doi.org/10.60110/medforum.360407",
"abstract": "<jats:p>Objective: To assess the anticoagulant effect of curcumin as adjuvant treatment to enoxaparin in COVID-19 patients. Study Design: Randomized open-labelled controlled trial study. Place and Duration of Study: This study was conducted at the College of Pharmacy, Al-Esraa University, Baghdad, Iraq from 1st February 2020 to 31st July 2020. Methods: Fifty-eight patients with confirmed Covid19 were enrolled into 2 groups: Group A; 29 patients were given Enoxaparin prophylactic dose 4000 IU twice daily every 12 hrs. Group B; 29 patients were given Enoxaparin prophylactic dose 4000 IU twice daily every 12 hrs + Curcumin 500 mg 3 times daily. Results: A significantly higher level of improvement in the outcomes of D-dimer serum level in the group treated with enoxaparin and curcumin in comparison with group A which was treated with enoxaparin alone (P<0.05). Conclusion: The overall results of this clinical study showed a significant D-dimer reduction by curcumin supplementation as well as reducing mortality and enhancing the overall clinical outcome of the treatment when used as an adjunct to enoxaparin. </jats:p>",
"author": [
{
"affiliation": [],
"family": "Baqer",
"given": "Maiss S.",
"sequence": "first"
},
{
"affiliation": [],
"family": "Dushan",
"given": "Saifan A",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Raad",
"given": "Rafif",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Noori Hameed",
"given": "Rabab Mohammed",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Ahmed",
"given": "Ayaashraf",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Dakhil",
"given": "Basim Dhawi",
"sequence": "additional"
}
],
"container-title": "Medical Forum Monthly",
"container-title-short": "mfm",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2025,
5,
26
]
],
"date-time": "2025-05-26T19:26:24Z",
"timestamp": 1748287584000
},
"deposited": {
"date-parts": [
[
2025,
5,
26
]
],
"date-time": "2025-05-26T19:29:56Z",
"timestamp": 1748287796000
},
"indexed": {
"date-parts": [
[
2025,
5,
26
]
],
"date-time": "2025-05-26T20:10:09Z",
"timestamp": 1748290209227,
"version": "3.41.0"
},
"is-referenced-by-count": 0,
"issue": "4",
"issued": {
"date-parts": [
[
2025,
4,
30
]
]
},
"journal-issue": {
"issue": "4",
"published-online": {
"date-parts": [
[
2025,
5,
26
]
]
}
},
"link": [
{
"URL": "http://medicalforummonthly.com/index.php/mfm/article/download/5253/4728",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "http://medicalforummonthly.com/index.php/mfm/article/download/5253/4728",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "39730",
"original-title": [],
"prefix": "10.60110",
"published": {
"date-parts": [
[
2025,
4,
30
]
]
},
"published-online": {
"date-parts": [
[
2025,
4,
30
]
]
},
"publisher": "Medical Academic Foundation",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "http://medicalforummonthly.com/index.php/mfm/article/view/5253"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Assessment of the Anticoagulant Effect of Curcumin as Adjuvant Therapy to Enoxaparinin Covid-19 Iraqi Patients",
"type": "journal-article",
"volume": "36"
}
